Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Individualized ASOs in Pediatric SDLT CNS Disorders
NCT07410143Phase 2Active, not recruiting
- Sponsor
- EveryONE Medicines
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of individualized antisense oligonucleotide in central nervous system disorder (CNSD), sponsored by EveryONE Medicines. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 48 weeks. Started Jan 2026; status: active, not recruiting.
02
Drugs
individualized antisense oligonucleotide
03
Conditions
central nervous system disorder (CNSD)
Beyond the preview
Go deeper on NCT07410143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07410143.